Skip to main content

TableĀ 2 Cost inputs

From: Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Country/costs (USD) Trastuzumab treatment Local recurrence Distance recurrence
Congo 20,000 974 1356
Ethiopia 20,000 1323 1841
Guinea 20,000 1136 1581
Kenya 20,000 2769 3853
Namibia 20,000 9719 13,524
Nigeria 20,000 5446 7578
Rwanda 20,000 1456 2027
Uganda 20,000 1424 1981
Zambia 20,000 2695 3751
Zimbabwe 20,000 2090 2909
South Africa 20,000 11,836 16,470